Fibrosing diseases are chronic pathologies, with a different genesis, characterized by various types of cellular or extracellular infiltrates determining a progressive destruction of the parenchyma, which is replaced by fibrous tissue, causing progressive damage to organ anatomy. Fibrosing diseases are one of the main causes of morbidity and mortality in the Western world.
To date, no effective drugs are available for the treatment of such diseases.
This invention relates to a novel use of 1-piperidin propionic acid as drug for the treatment of fibrosing diseases. The compound acts on SerpinB3, which has been identified as an effective target, it reduces the expression of said molecule and limits fibrotic damage.